A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Seppi K, Monnet A, Shariati N, Ricci B, Rutten-Jacobs L, Respondek G, Kustermann T, Taylor KI, Trundell D, Fontoura P, Doody R, Svoboda H, Bonni A; PADOVA Investigators and Prasinezumab Study Group.
Nikolcheva T, et al. Among authors: pagano g.
Parkinsonism Relat Disord. 2024 Dec 29;132:107257. doi: 10.1016/j.parkreldis.2024.107257. Online ahead of print.
Parkinsonism Relat Disord. 2024.
PMID: 39798255
Free article.